Practice

Multiple Studies Highlight Economic Benefits of Biosimilar Infliximab

November 13th 2018

By Kelly Davio

This week, healthcare economics stakeholders have gathered in Barcelona, Spain, for the 2018 annual European meeting of the International Society for Pharmacoeconomics and Outcomes Research. During the meeting, research teams from around the globe are presenting findings that support the use of biosimilar infliximab as a cost-saving measure.

Existing Data Support the Use of Biosimilars in Pediatric IBD

November 12th 2018

By Kelly Davio

Article

Early-onset inflammatory bowel disease (IBD) can have a more aggressive course than later-onset disease, making prompt treatment for children with IBD especially important. Given the high cost of biologics that treat pediatric IBD—adalimumab and infliximab—biosimilars are emerging as an important cost-saving option that can prevent the premature termination of biologic therapy for financial reasons.

Community Oncologists Divided on the Value of Biosimilars

November 9th 2018

By Samantha DiGrande

Article

During the Community Oncology Alliance Payer Summit, held October 29-30, 2018, The Center for Biosimilars® had the opportunity to sit down with several oncologists to discuss their opinions on and experiences with biosimilars.

Pharmacist Involvement Improves Reimbursement of Biologics, Paper Says

November 6th 2018

By Kelly Davio

Article

At the Department of Abdominal Oncology at the National Cancer Institute of Naples in Italy, an expert pharmacist was involved in evaluating the economic impact of improving the Italian registry of high-cost drugs, particularly bevacizumab, cetuximab, panitumumab, and trastuzumab.

Autoinjector, Prefilled Syringe Administration of Imraldi Have Similar PK and Safety

November 5th 2018

By Kelly Davio

Article

Samsung Bioepis, maker of Imraldi, has developed an autoinjector device that aims to address some of the mobility limitations that patients with rheumatoid arthritis may have in self-administering their adalimumab with a syringe.

Paper Raises Unanswered Questions About Subcutaneous Trastuzumab

November 4th 2018

By The Center for Biosimilars Staff

Article

While US patients with HER2-positive cancers do not have an available subcutaneous trastuzumab option, Brazil, Canada, and the European Union have an approved product that has been shown in a phase 3 trial to be noninferior to intravenous trastuzumab.

Biosimilars Can Play a Key Role in Value-Based Care, Review Says

November 1st 2018

By Kelly Davio

Article

Given the high burden of cancer in the senior population, and given the increasingly high cost of cancer care, there is a growing interest in value-based oncology care payment models, particularly within CMS.

Rituximab Is Effective in Treating Cutaneous Lupus Erythematosus, Study Finds

October 31st 2018

By Kelly Davio

Article

Current treatment for cutaneous lupus erythematosus (CLE) commonly focuses on photoprotection, topical therapies, corticosteroids, antimalarial drugs, and immunosuppressive drugs. More recently, B-cell depleting therapies, such as rituximab, have shown promise in treating systemic lupus erythematosus, though the feasibility of treating CLE with rituximab has not been well described.

Biosimilar Rheumatology Roundup: October 2018

October 31st 2018

By Kelly Davio

Article

With the launch of some of the most highly anticipated products thus far in the biosimilar experience, and with the release of key new data on multiple biosimilar products, October 2018 was a memorable month for biosimilar stakeholders.

Study: New Patients Treated With CT-P13 Discontinued Treatment More Often

October 30th 2018

By Kelly Davio

Article

A recent population-based study examined the prescribing and utilization of CT-P13 versus the reference infliximab in infliximab-naïve patients and found that discontinuation and switching were more common among patients who began therapy with the biosimilar.